Novo CEO Doustdar On What’s New For Ozempic, Wegovy, GLP-1s, Obesity

Health By Bruce Y. Lee, Senior Contributor • November 12, 2026, 1:30 PM UTC
⏱ 1 min read 👁 4 views
Direct Source Verification: This story is aggregated from Forbes (forbes.com). Full reporting rights and copyright belong to the primary publisher.
Read on Forbes ↗
Novo CEO Doustdar On What’s New For Ozempic, Wegovy, GLP-1s, Obesity
Novo president and chief executive officer Mike Doustdar talked about Ozempic, Wegovy, new GLP-1 medications, weight loss and obesity and the company's new rebrand
Novo president and chief executive officer Mike Doustdar talked about Ozempic, Wegovy, new GLP-1 medications, weight loss and obesity and the company's new rebrand
Original Source
https://www.forbes.com/sites/brucelee/2026/11/12/novo-ceo-doustdar-on-whats-new-for-ozempic-wegovy-glp-1s-obesity/
Visit Forbes ↗
SHARE STORY:
𝕏 f in

Related Coverage in Health